HALO logo
halo search icon
Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc.
RNA · NAS

Atrium Therapeutics, Inc.

US$12.72

Price Arrow-0.23 (-1.776%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusEngulfing Bullish (Realtime)HALO AllHALO Consensus ValueRecent Earnings downgrade
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Atrium Therapeutics, Inc. Overview

RNA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About RNA

icon

Website

Atrium Therapeutics, Inc.

icon

Telephone

1.619.876.0700

icon

Address

Suite 125, 10578 Science Center Drive, San Diego, CA 92121

Description

Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.

RNA Price Chart

Key Stats

Market Cap

US$221.52M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 11.95 - 16.77

Trade Value (12mth)

US$602,431.00

1 week

-2.12%

1 month

-4.29%

YTD

-12.2%

1 year

0%

All time high

16.77

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

-264.80%

Operating Cashflow

-$41m

Free Cash Flow Return

0.00%

ROIC

0.00%

Interest Coverage

0.00

Quick Ratio

0.00

Other Data

Shares Outstanding (Fully Diluted)

17m

HALO Sector

Healthcare

Next Company Report Date

03-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

RNA Announcements

Latest Announcements

DateAnnouncements
15 May 26
15 May 26
15 May 26
15 May 26
15 May 26

RNA Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-0.37-1.47-2.89locklocklock
EPS (Fully Diluted)
$locklocklocklock-0.37-1.47-2.89locklocklock
Growth
%locklocklocklockN/A-293.4-97locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Atrium Therapeutics, Inc. (RNA:NAS)?
Halo FAQ
The current share price of Atrium Therapeutics, Inc. (RNA:NAS) is USD$12.72.
What is the 52-week high share price for Atrium Therapeutics, Inc. (RNA:NAS)?
Halo FAQ
The 52-week high share price for Atrium Therapeutics, Inc. (RNA:NAS) is USD$16.77.
What is the 52-week low share price for Atrium Therapeutics, Inc. (RNA:NAS)?
Halo FAQ
The 52-week low share price for Atrium Therapeutics, Inc. (RNA:NAS) is USD$11.95.
What is the dividend yield for Atrium Therapeutics, Inc. (RNA:NAS)?
Halo FAQ
Atrium Therapeutics, Inc. (RNA:NAS) does not pay a dividend.
What was Atrium Therapeutics, Inc. (RNA:NAS) last dividend payment?
Halo FAQ
Atrium Therapeutics, Inc. (RNA:NAS) does not pay a dividend.
What is the franking level for Atrium Therapeutics, Inc. (RNA:NAS)?
Halo FAQ
Atrium Therapeutics, Inc. (RNA:NAS) has a franking level of 0.00%.
In which sector is Atrium Therapeutics, Inc. (RNA:NAS) classified?
Halo FAQ
Atrium Therapeutics, Inc. (RNA:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.